Home / Weight & metabolism / ATX-304
AtHuman trials

ATX-304 protocol

ATX-304 is an experimental pill that switches on AMPK, an energy sensor in cells. It has had a small phase 1b trial. It is not approved.

Not approved anywhere (investigational)Phase 1b finished (EU); phase 2 planned by the company
ProtocolMixingResultsSide effectsHow it worksSources

The protocol at a glance

In the phase 1b trial, 23 adults with obesity and prediabetes took ATX-304 or placebo once a day for 8 weeks. The company reports 400 mg tablets.

StudyDaily amount
Phase 1b, 8 weeks (23 adults)400 mg tablet once a day, per company reports
Older version O304, phase 2a, 28 daysDose not found in the sources read
Human dose beyond thisNot established

The 400 mg dose comes from company news coverage of the ADA 2026 poster (abstract 1782-P). The EU registry entry (2023-505967-36-00) says tablets but hides the dose until 2027. No peer-reviewed paper yet.

Community reports

Community notes suggest wide ranges of daily doses. This is community talk; only one dose appears in the company data.

What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.

Mixing

No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.

What the trials found

Phase 1b, 23 adults with obesity and prediabetes, 8 weeks. Company-reported, not peer-reviewed:

+8%resting metabolic rate
23adults in the trial
0peer-reviewed human results yet

Cambrian Bio release, June 2026 (via Longevity.Technology and Business Wire coverage). The company also reported better liver fat, belly fat, triglycerides and adiponectin, with no numbers in what I could read. Weight loss was minimal at this dose.

Side effects

  • The company says side effects were mostly mild and similar to placebo. It reported no problems with core body temperature or heart rate.
  • These are company statements from a very small trial. Long-term safety is unknown.

How it works

AMPK

It switches on AMPK, a cell energy sensor. In mice it raised fat burning in the liver and lowered fat mass.

Sources

  • Cambrian Bio / Business Wire release, 18 June 2026: ATX-304 phase 1b data at ADA 2026 (abstract 1782-P)
  • Longevity.Technology: Human data validate Cambrian Bio's aging target (2026)
  • EU CTIS trial 2023-505967-36-00 (ATX-304 Na salt tablets, phase 1b)
  • AMPK activator ATX-304 reduces oxidative stress and improves MASLD via metabolic switching. JCI Insight 2025 (PubMed 40197369)